단일 세포 시퀀싱 시장 : 전략적 인사이트와 예측(2026-2035년)

The Single-Cell Sequencing Market is estimated to grow to USD 13.23 billion in 2035 at a CAGR of 13.9% from USD 4.11 billion in 2026.

Single-cell sequencing has revolutionized genomic research by enabling the analysis of DNA, RNA, epigenetic modifications, and other molecular characteristics at the level of individual cells. Unlike conventional bulk sequencing, single-cell technologies reveal cellular diversity within tissues, allowing researchers to identify rare cell populations, understand disease progression, and develop highly targeted therapies. The technology is becoming indispensable in oncology, immunology, neuroscience, developmental biology, and regenerative medicine. Continued improvements in microfluidics, sequencing chemistry, automation, artificial intelligence (AI), and bioinformatics are expanding both research and clinical applications of single-cell sequencing.

Market Drivers

Growing Adoption of Precision Medicine

Precision medicine requires highly detailed molecular profiling to personalize diagnosis and treatment. Single-cell sequencing enables clinicians and researchers to understand disease biology at unprecedented resolution, supporting biomarker discovery and individualized therapeutic strategies.

Rising Cancer and Immunology Research

Cancer tissues exhibit substantial cellular heterogeneity that influences disease progression and treatment response. Single-cell sequencing allows researchers to identify tumor subpopulations, immune cell interactions, and mechanisms of drug resistance, significantly advancing oncology research. Immunology is also benefiting from improved characterization of immune cell populations and immune responses.

Continuous Technological Advancements

Innovations in droplet-based sequencing, microfluidics, high-throughput library preparation, and sequencing chemistries have improved scalability, accuracy, and cost efficiency. These advances are making single-cell sequencing accessible to a broader range of research and clinical laboratories.

Increasing Investment in Genomics Research

Governments, academic institutions, pharmaceutical companies, and biotechnology firms continue investing heavily in genomics research, cell atlas projects, and precision medicine initiatives, creating sustained demand for advanced single-cell sequencing platforms.

Market Restraints

High Cost of Sequencing Workflows

Single-cell sequencing requires specialized instruments, reagents, computational infrastructure, and highly trained personnel. The overall cost remains a significant barrier for smaller laboratories and healthcare providers.

Complex Data Analysis

The large volume and complexity of single-cell datasets require sophisticated bioinformatics pipelines, cloud computing infrastructure, and advanced statistical analysis, increasing implementation complexity.

Lack of Standardized Clinical Workflows

Although research adoption is accelerating rapidly, standardized protocols, quality control procedures, and clinical validation continue to evolve before routine diagnostic implementation.

Market and Technology Insights

The global single-cell sequencing market can be segmented by product, workflow, sequencing type, application, end user, and geography.

By product, the market includes instruments, reagents & kits, software, and services. Reagents and kits account for the largest revenue share because they are required throughout sequencing workflows, while bioinformatics software continues expanding with increasing demand for automated data analysis.

By workflow, the market comprises single-cell isolation, sample preparation, genomic amplification, library preparation, sequencing, and bioinformatics analysis. Improvements across each workflow stage continue reducing turnaround time while increasing throughput and reproducibility.

By sequencing type, the market includes single-cell RNA sequencing (scRNA-seq), single-cell DNA sequencing (scDNA-seq), single-cell epigenomics, and multi-omics sequencing. Single-cell RNA sequencing remains the dominant segment due to its widespread application in gene expression profiling and cell atlas initiatives.

By application, the market serves oncology, immunology, neurology, developmental biology, stem cell research, infectious diseases, and precision medicine research. Oncology represents the leading application because of growing interest in tumor heterogeneity, biomarker discovery, and therapeutic resistance.

By end user, the market includes academic & research institutes, pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, and contract research organizations (CROs). Academic institutions remain the largest users, while pharmaceutical companies continue expanding adoption for drug discovery and biomarker development.

Market Trends

The single-cell sequencing market continues to evolve through rapid technological innovation.

Key trends include:

• Increasing integration of artificial intelligence and machine learning.
• Expansion of spatial transcriptomics.
• Growth of single-cell multi-omics platforms.
• Higher-throughput sequencing workflows.
• Increasing automation of sample preparation.
• Expansion of precision oncology applications.
• Growing cloud-based bioinformatics platforms.

Regional Insights

North America remains the largest market because of strong genomics research funding, advanced sequencing infrastructure, widespread precision medicine adoption, and the presence of major sequencing technology companies.

Europe continues to experience strong growth through collaborative genomics initiatives, expanding life sciences research, and increasing adoption of advanced sequencing technologies across academic and clinical institutions.

Asia-Pacific is expected to register the fastest growth owing to increasing biotechnology investments, expanding genomic research infrastructure, improving healthcare systems, and growing government support for precision medicine. China, Japan, South Korea, India, and Australia are driving regional market expansion.

Latin America and the Middle East & Africa are gradually strengthening sequencing capabilities through healthcare modernization, research collaborations, and increasing investment in molecular diagnostics.

Competitive Landscape

The market is characterized by continuous innovation in sequencing platforms, microfluidics, sample preparation technologies, and bioinformatics.

Major companies include 10x Genomics, Illumina, Thermo Fisher Scientific, Bio-Rad Laboratories, Standard BioTools (formerly Fluidigm), Oxford Nanopore Technologies, Parse Biosciences, Becton Dickinson (BD), QIAGEN, Pacific Biosciences (PacBio), Mission Bio, and Roche. Companies continue investing in automation, multi-omics platforms, AI-powered analytics, and strategic collaborations to expand their competitive positions.

Future Outlook

The future of the single-cell sequencing market will be driven by broader adoption in clinical diagnostics, expansion of spatial and multi-omics technologies, improvements in sequencing affordability, and increasing integration of AI-powered bioinformatics. As researchers continue generating comprehensive cellular atlases and precision medicine becomes more widespread, single-cell sequencing is expected to become an increasingly important component of disease diagnosis, biomarker discovery, and therapeutic development.

Conclusion

The Global Single-Cell Sequencing Market is expected to witness robust growth through 2035, supported by increasing demand for high-resolution cellular analysis, expanding precision medicine programs, and continuous advances in sequencing technologies. Although challenges related to cost, computational complexity, and workflow standardization remain, ongoing innovation in sequencing platforms, automation, and bioinformatics is expected to create substantial opportunities for sequencing technology providers, pharmaceutical companies, healthcare organizations, researchers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global single-cell sequencing market.
• Detailed evaluation of technologies, workflows, and emerging innovations.
• Analysis of competitive strategies, technological developments, and commercialization opportunities.
• Insights into precision medicine, oncology, immunology, and multi-omics applications.
• Valuable resource for sequencing technology companies, biotechnology firms, healthcare providers, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, product portfolio planning, competitive benchmarking, precision medicine strategy, drug discovery support, partnership evaluation, commercialization planning, investment analysis, regulatory planning, and long-term business decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2026, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global single-cell sequencing market by product, workflow, sequencing type, application, end user, and geography
• Evaluation of market dynamics, technology innovation, competitive landscape, regulatory environment, and future growth opportunities
• Assessment of single-cell RNA sequencing, single-cell DNA sequencing, multi-omics, spatial transcriptomics, AI-enabled bioinformatics, automation, and commercialization strategies
• Analysis of instruments, reagents & kits, software, services, oncology, immunology, neurology, developmental biology, pharmaceutical research, academic research, and emerging single-cell sequencing technologies through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Single-Cell Sequencing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Single-Cell Omics Ecosystem Overview
• 3.8 Sequencing Workflow Overview
• 3.9 Testing Volume Analysis
• 3.10 User Adoption Analysis
• 3.11 Precision Medicine and Functional Genomics Landscape
• 3.12 Clinical and Research Applications Landscape

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in Single-Cell Sequencing
• 6.2 Product Innovation Analysis
• 6.3 Single-Cell Multi-Omics Advancements
• 6.4 Microfluidics and Cell Isolation Innovations
• 6.5 Spatial Biology Integration Trends
• 6.6 Clinical Trial Analysis
• 6.7 Pipeline Analysis
• 6.8 AI Integration in Single-Cell Data Analysis
• 6.9 Digital Health and Bioinformatics Integration
• 6.10 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Single-Cell Sequencing Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Sequencing Type
• 8.3 Analysis by Omics Modality
• 8.4 Analysis by Cell Isolation Method
• 8.5 Analysis by Application
• 8.6 Analysis by Workflow Stage
• 8.7 Analysis by End User

9. Single-Cell Sequencing Market Segment Analysis (2021-2035)

• 9.1 By Product & Service
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software & Bioinformatics Solutions
  • 9.1.4 Sequencing Services
• 9.2 By Sequencing Type
  • 9.2.1 Single-Cell RNA Sequencing (scRNA-seq)
  • 9.2.2 Single-Cell DNA Sequencing (scDNA-seq)
  • 9.2.3 Single-Cell Epigenomics Sequencing
  • 9.2.4 Single-Cell Multi-Omics Sequencing
• 9.3 By Cell Isolation Technology
  • 9.3.1 Microfluidics-Based Isolation
  • 9.3.2 Fluorescence-Activated Cell Sorting (FACS)
  • 9.3.3 Magnetic-Activated Cell Sorting (MACS)
  • 9.3.4 Laser Capture Microdissection
  • 9.3.5 Other Isolation Technologies
• 9.4 By Application
  • 9.4.1 Oncology
  • 9.4.2 Immunology
  • 9.4.3 Neurology
  • 9.4.4 Stem Cell Research
  • 9.4.5 Developmental Biology
  • 9.4.6 Rare Disease Research
  • 9.4.7 Infectious Disease Research
  • 9.4.8 Other Applications
• 9.5 By End User
  • 9.5.1 Academic & Research Institutes
  • 9.5.2 Pharmaceutical & Biotechnology Companies
  • 9.5.3 Hospitals & Clinical Laboratories
  • 9.5.4 Contract Research Organizations (CROs)
  • 9.5.5 Other End Users

10. Single-Cell Sequencing Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Single-Cell Sequencing Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Switzerland
• 11.7 China
• 11.8 Japan
• 11.9 South Korea
• 11.10 India
• 11.11 Singapore
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 10x Genomics, Inc.
• 13.2 Illumina, Inc.
• 13.3 Bio-Rad Laboratories, Inc.
• 13.4 Standard BioTools Inc.
• 13.5 Parse Biosciences, Inc.
• 13.6 Mission Bio, Inc.
• 13.7 Takara Bio Inc.
• 13.8 QIAGEN N.V.
• 13.9 Thermo Fisher Scientific Inc.
• 13.10 Oxford Nanopore Technologies plc
• 13.11 Pacific Biosciences of California, Inc.
• 13.12 Singleron Biotechnologies Co., Ltd.
• 13.13 Scale Biosciences, Inc.
• 13.14 BD (Becton, Dickinson and Company)
• 13.15 Dolomite Bio

14. Single-Cell Sequencing Market Commercial Forecast Analysis

• 14.1 Forecast by Instruments
• 14.2 Forecast by Reagents & Consumables
• 14.3 Forecast by Software & Bioinformatics Solutions
• 14.4 Forecast by Sequencing Services
• 14.5 Forecast by Single-Cell RNA Sequencing Applications
• 14.6 Forecast by Single-Cell DNA Sequencing Applications
• 14.7 Forecast by Oncology Applications
• 14.8 Forecast by Immunology Applications

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends